77,997 Shares in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA Acquired by Spruce Street Capital LP

Spruce Street Capital LP bought a new position in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor bought 77,997 shares of the company’s stock, valued at approximately $1,951,000. Centessa Pharmaceuticals accounts for about 0.6% of Spruce Street Capital LP’s holdings, making the stock its 23rd largest position. Spruce Street Capital LP owned about 0.06% of Centessa Pharmaceuticals at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. TD Waterhouse Canada Inc. purchased a new stake in Centessa Pharmaceuticals during the 4th quarter worth approximately $25,000. Caitong International Asset Management Co. Ltd purchased a new stake in Centessa Pharmaceuticals during the 4th quarter worth approximately $36,000. Wells Fargo & Company MN increased its stake in Centessa Pharmaceuticals by 42.4% during the 4th quarter. Wells Fargo & Company MN now owns 3,387 shares of the company’s stock worth $85,000 after buying an additional 1,008 shares during the period. Knott David M Jr purchased a new stake in Centessa Pharmaceuticals during the 4th quarter worth approximately $100,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in Centessa Pharmaceuticals by 26.4% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,688 shares of the company’s stock worth $117,000 after buying an additional 979 shares during the period. 82.01% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, insider Karen M. Anderson sold 41,076 shares of the stock in a transaction that occurred on Thursday, March 26th. The shares were sold at an average price of $30.12, for a total value of $1,237,209.12. Following the sale, the insider directly owned 62,085 shares of the company’s stock, valued at approximately $1,870,000.20. This represents a 39.82% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 4.09% of the company’s stock.

Centessa Pharmaceuticals Trading Up 0.1%

Shares of NASDAQ:CNTA opened at $39.76 on Tuesday. Centessa Pharmaceuticals PLC Sponsored ADR has a 52 week low of $12.05 and a 52 week high of $40.26. The company’s 50 day moving average is $39.64 and its two-hundred day moving average is $30.96. The company has a current ratio of 9.53, a quick ratio of 9.53 and a debt-to-equity ratio of 0.23. The company has a market cap of $6.15 billion, a PE ratio of -22.21 and a beta of 1.11.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.14). Equities analysts predict that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. Stephens downgraded shares of Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, March 31st. Guggenheim downgraded shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, April 2nd. Wolfe Research downgraded shares of Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating in a research note on Tuesday, March 31st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research note on Monday, April 20th. Finally, Wells Fargo & Company downgraded shares of Centessa Pharmaceuticals from an “overweight” rating to an “equal weight” rating and increased their price objective for the company from $35.00 to $42.00 in a research report on Monday, April 20th. Four research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $41.33.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc is a global clinical?stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision?making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.